SCHEMBL5202887

SCHEMBL5202887

O=C1c2cccc(N3CCNCC3)c2CCN1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHPS P49366 1/20 0.54
SMN1; SMN2 Q16637 5/20 0.52
LMNA P02545 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
NCOA3 Q9Y6Q9 1/20 0.52
HTR6 P50406 6/20 0.51
PKM P14618 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 4/20 0.46
HTT P42858 2/20 0.46
HTR1A P08908 2/20 0.46
HTR2A P28223 1/20 0.46
HTR7 P34969 1/20 0.46
HTR5A P47898 1/20 0.46
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201380 0.83 DRD3 (0.54) DHPSSMN1; SMN2LMNAL3MBTL1NCOA3
SCHEMBL4991491 0.77 DHPS (0.60) DHPSSMN1; SMN2LMNAL3MBTL1NCOA3
SCHEMBL3000762 0.77 DHPS (0.60) DHPSSMN1; SMN2LMNAL3MBTL1NCOA3
SCHEMBL2998761 0.76 DHPS (0.62) DHPSSMN1; SMN2LMNAL3MBTL1NCOA3
SCHEMBL14253731 0.75 HTR6 (0.63) SMN1; SMN2L3MBTL1HTR6HTR1AHTR2A
SCHEMBL5812457 0.74 DHPS (0.58) DHPSSMN1; SMN2LMNAL3MBTL1NCOA3
SCHEMBL3857908 0.73 HTR6 (0.65) L3MBTL1HTR6MEN1KMT2AALDH1A1
SCHEMBL23952349 0.72 SMN1; SMN2 (0.89) DHPSSMN1; SMN2LMNAL3MBTL1NCOA3
SCHEMBL4613615 0.72 HTR6 (0.57) HTR6HTR1AHTR2AHTR7HTR5A
SCHEMBL30083042 0.72 HTR7 (0.50) LMNAHTR6ALDH1A1HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP claimed
EP-1601358-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-07 EP claimed
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC 2004-09-16 US claimed
WO-2004078176-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-16 WO claimed
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
EP-1601358-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-07 EP disclosed
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC 2004-09-16 US disclosed
WO-2004078176-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof CYP3A5, CYP4X1, UGT1A1 DHPS 397/4885SMN1; SMN2 2287/4885LMNA 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.